• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Biol Sci . Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2

tetano

Editor, Senior Moderator
Int J Biol Sci


. 2022 Sep 1;18(15):5591-5606.
doi: 10.7150/ijbs.78002. eCollection 2022.
Serological responses to human virome define clinical outcomes of Italian patients infected with SARS-CoV-2


Limin Wang[SUP] 1 2 [/SUP], Julián Candia[SUP] 1 2 [/SUP], Lichun Ma[SUP] 1 2 [/SUP], Yongmei Zhao[SUP] 3 2 [/SUP], Luisa Imberti[SUP] 4 [/SUP], Alessandra Sottini[SUP] 4 [/SUP], Eugenia Quiros-Roldan[SUP] 5 [/SUP], Kerry Dobbs[SUP] 6 [/SUP], Peter D Burbelo[SUP] 7 [/SUP], Jeffrey I Cohen[SUP] 8 [/SUP], Ottavia M Delmonte[SUP] 6 [/SUP], Marshonna Forgues[SUP] 1 [/SUP], Hui Liu[SUP] 6 [/SUP], Helen F Matthews[SUP] 9 [/SUP], Elana Shaw[SUP] 6 [/SUP], Michael A Stack[SUP] 6 [/SUP], Sarah E Weber[SUP] 10 [/SUP], Yu Zhang[SUP] 6 [/SUP], Andrea Lisco[SUP] 11 [/SUP], Irini Sereti[SUP] 11 [/SUP], Helen C Su[SUP] 6 [/SUP], Luigi D Notarangelo[SUP] 6 [/SUP], Xin Wei Wang[SUP] 1 12 13 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 sequentially enrolled hospitalized patients with COVID-19-associated pneumonia from Brescia, Italy using the VirScan phage-display method to characterize circulating antibodies binding to 96,179 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection was associated with a marked increase in immune antibody repertoires against many known pathogenic and non-pathogenic human viruses. This antiviral antibody response was linked to longitudinal trajectories of disease severity and was further confirmed in additional 125 COVID-19 patients from the same geographical region in Northern Italy. By applying a machine-learning-based strategy, a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival was developed and validated. These results provide a basis for understanding the role of memory B-cell repertoire to viral epitopes in COVID-19-related symptoms and suggest that a unique anti-viral antibody repertoire signature may be useful to define COVID-19 clinical severity.
 
Back
Top Bottom